Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36511784/
In patients with relapsed or refractory CLL or SLL, progression-free survival was significantly longer among patients who received zanubrutinib than among those who received ibrutinib, and zanubrutinib was associated with...
Conclusions: In patients with relapsed or refractory CLL or SLL, progression-free survival was significantly longer among patients who received zanubrutinib than among those who received ibrutinib, and zanubrutinib was associated with fewer cardiac adverse events.
Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders
Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.1068981/full
In the category of mature B-cell neoplasms, splenic B-cell lymphoma and leukemia were clearly identified and include four distinct entities: hairy cell leukemia (HCL), splenic marginal zone lymphoma (SMZL), splenic...
Conclusions: Chemotherapy with PNA monotherapy or associated with anti-CD20 stay the gold standard in the frontline setting. Thanks to the recent discoveries in genetics and signaling pathways in HCL and HCL-like disorders, new targeted therapies have been developed and have proven their efficacy and safety in several clinical trials: BRAFi,...
Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
Source : https://cdrjournal.com/article/view/5221
The lysine [K]-methyltransferase 2A (KMT2A)/mixed-lineage leukemia 1 (KMT2A/MLL) gene on chromosome 11 encodes a 431-kDa protein involved in the regulation of transcription. Rearrangements (r) of the KMT2A/MLL gene have been...
Conclusions: These results provide new insights regarding the clinical potential of small molecule inhibitors of these PTK, many of which are already FDA/EMA-approved for other indications, as components of innovative multi-modality treatment platforms against KMT2A/MLL-R acute leukemias.
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36588395/
Bortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, Bruton Tyrosine Kinase inhibitors, carfilzomib, lenalidomide, bendamustine, and venetoclax have all been shown to have activity in relapsed WM. Given WM's natural history, the reduction...
Conclusions: Management of refractory disease: Bortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, Bruton Tyrosine Kinase inhibitors, carfilzomib, lenalidomide, bendamustine, and venetoclax have all been shown to have activity in relapsed WM. Given WM's natural history, the reduction of therapy toxicity is an important part of...
-
Leukemia and Lymphoma Connect3yrKey Points • Source: American Journal of Hematology • Conclusion: “When WM is diagnosed before the development of symptoms, patients may be safely observed and monitored. However, patients with symptoms require chemotherapy.” • Waldenström macroglobulinemia (WM) Show More
ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36588692/
Hyperactivation of Bruton's tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton's tyrosine...
Conclusions: Oral administration of ASK120067 led to significant tumor regression in B-cell lymphoma and T-cell leukemia xenograft models by weakening Bruton's tyrosine kinase and interleukin-2-inducible T cell kinase signaling, respectively. Taken together, our studies demonstrated that ASK120067 exerted preclinical anti-tumor activities...